

Cases from the Community: Investigators Discuss Available Research Guiding the Care of Patients with Gastroesophageal and Hepatobiliary Cancers — A 2023 Post-ASCO GI Webcast

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following metrics was significantly improved with the addition of zolbetuximab to first-line chemotherapy for patients with advanced HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma in the Phase III SPOTLIGHT trial?
 - a. Overall response rate
 - b. Progression-free survival and overall survival
 - c. Progression-free survival, overall survival and response rate

2. Which of the following statements best describes the frequency of any-grade adverse events with durvalumab/tremelimumab compared to sorafenib in the Phase III HIMALAYA trial?
 - a. Frequency was significantly decreased with durvalumab/tremelimumab
 - b. Frequency was significantly increased with durvalumab/tremelimumab
 - c. Frequency was similar between durvalumab/tremelimumab and sorafenib

3. What was the rate of interstitial lung disease (ILD) with trastuzumab deruxtecan for Western patients in the Phase II DESTINY-Gastric02 trial with advanced HER2-positive gastric or GEJ cancer whose disease had progressed after a trastuzumab-containing regimen?
 - a. No ILD was observed
 - b. Approximately 8%
 - c. Approximately 30%

4. Which of the following statements best describes overall survival results with tislelizumab compared to sorafenib for patients with previously untreated hepatocellular carcinoma in the Phase III RATIONALE 301 trial?
 - a. Tislelizumab was inferior to sorafenib
 - b. Tislelizumab was noninferior to sorafenib
 - c. Tislelizumab was superior to sorafenib

5. Which of the following types of toxicity was most commonly observed with the addition of zolbetuximab to chemotherapy for patients with previously untreated HER2-negative advanced gastric/GEJ adenocarcinoma in the Phase III SPOTLIGHT trial?
 - a. Ocular
 - b. Neurologic
 - c. Hematologic
 - d. Gastrointestinal